FitLife Brands, Inc. (FTLF) - 10-K Summary
Business Context and Reporting Period
Company: FitLife Brands, Inc.
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: FitLife Brands is a provider of nutritional supplements and wellness products operating under four primary brand collections: NDS Products (distributed via GNC), iSatori Products (retail and online), MRC Products (primarily Amazon), and MusclePharm (wholesale and online). The company operates as a single reporting segment.
Recent Corporate Action: On February 7, 2025, the company effected a 2-for-1 stock split. All share data in this filing has been retroactively adjusted.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $64,469 | $52,700 |
| Gross Profit | $28,080 | $21,432 |
| Gross Margin | 43.6% | 40.7% |
| Operating Income | $13,119 | $7,550 |
| Net Income | $8,984 | $5,296 |
| Diluted EPS | $0.91 | $0.54 |
| Operating Cash Flow | $9,610 | $4,220 |
| Total Debt (Term Loans) | $13,125 | $20,125 |
| Cash and Equivalents | $4,468 | $1,139 |
| Working Capital | $6,832 | $4,356 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 22% to $64.5 million, driven primarily by the full-year contribution of MRC (acquired Feb 2023) and the inclusion of MusclePharm (acquired Oct 2023). Legacy FitLife revenue declined 10% due to a 16% drop in wholesale sales.
- Profitability: Net income surged 70% to $9.0 million. Operating income increased 74% to $13.1 million, aided by higher gross margins and a significant reduction in merger and acquisition-related expenses ($255k in 2024 vs. $1.6M in 2023).
- Debt Reduction: The company voluntarily prepaid $2.5 million on Term Loan A and made scheduled amortization payments, reducing total term loan debt from $20.1 million to $13.1 million.
- Customer Concentration: Sales to GNC decreased from 33% of total revenue in 2023 to 23% in 2024. Conversely, online revenue (including Amazon) grew to 67% of total revenue.
Outlook, Risks, and Management Commentary
- Commercial Dispute Resolution: A commercial dispute with GNC in Q4 2024 led to a temporary halt in purchase orders. The dispute was settled on January 23, 2025, and shipments resumed. The company temporarily shipped directly to franchisees to maintain shelf availability.
- Strategic Initiatives: Management is optimizing the MRC portfolio by exiting unprofitable international markets for skincare brands, which improved gross margins. MusclePharm is undergoing promotional investments to drive wholesale growth, including a new "Pro Series" pilot at Vitamin Shoppe stores in March 2025.
- Liquidity: The company maintains a $3.5 million revolving line of credit (extended to April 2026) with no outstanding balance as of year-end. Management believes cash flow from operations and available credit are sufficient for the next 12 months.
- Key Risks:
- Platform Dependency: Approximately 66% of total sales occurred via Amazon's U.S. marketplace in 2024. Suspension or termination of this account would have a material adverse effect.
- Customer Concentration: GNC remains a critical wholesale partner, accounting for 23% of sales and a significant portion of accounts receivable.
- Supply Chain: Reliance on a limited number of third-party manufacturers for production.
Investor Verification Checklist
- GNC Relationship Status: Verify the stability of the renewed relationship with GNC following the Q4 2024 dispute and the impact of the direct-to-franchisee shipping model.
- Amazon Dependency: Assess the risk exposure given that two-thirds of revenue is generated through a single third-party platform (Amazon).
- Debt Covenants: Confirm ongoing compliance with the Fixed Charge Coverage Ratio (1.25:1) and Funded Debt to EBITDA Ratio (2.50:1) covenants under the Amended Credit Agreement.
- Legacy Brand Performance: Monitor the trajectory of Legacy FitLife wholesale revenue, which has declined 16% year-over-year, to determine if the trend is reversing.
- Inventory Valuation: Review the allowance for obsolescence ($100k) and the critical audit matter regarding inventory valuation, particularly for slow-moving items.